510(k) Report

510(k) · Cleared

Cleared

SimulCare II (TM)

K160246510(k) TraditionalCleared Oct 6, 2016248-day reviewClass II21 CFR 882.5890

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Xanacare Technologies, LLC · GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief

Cleared on Oct 6, 2016 as substantially equivalent to K083202 (Xanacare Technologies, LLC, 2008) and 1 other predicate after a 248-day review. Its family tree reaches back 7 generations to 2000.

Decided
Oct 6, 2016
Review
248 days
Class
Class II
Product code
GZJ
Recalls
None
Predicates
2

Its longest line of descent runs back 7 generations to K001179 (2000). 18 ancestors in all, the oldest K881114 (1988). No later device cites it as a predicate yet.

  1. Root · 7 generations backK001179 Super Nova, AcubeamLight Force Therapy, Inc. · 2000
  2. 6 generations backK020017 Medx 1000 SeriesMedx Electronics, Inc. · 2002
  3. 5 generations backK032816 Quantum Light Therapy SystemStargate International, Inc. · 2004
  4. 4 generations backK041530 Excalibur Light Therapy System, Model Sgiex-04-001Stargate International, Inc. · 2004
  5. 3 generations backK050668 GRT Lite, Model 8-aGrt Solutions, Inc. · 2006
  6. 2 generations backK081141 Combocare 2000Xanacare Technologies, LLC · 2008
  7. 1 generation backK083202 Combocare 2000Xanacare Technologies, LLC · 2008
  8. This deviceK160246 SimulCare II (TM)Xanacare Technologies, LLC · 2016
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−7K001179Super Nova, AcubeamLight Force Therapy, Inc.2000—
−6K020017Medx 1000 SeriesMedx Electronics, Inc.2002—
−5K032816Quantum Light Therapy SystemStargate International, Inc.2004—
−4K041530Excalibur Light Therapy System, Model Sgiex-04-001Stargate International, Inc.2004—
−3K050668GRT Lite, Model 8-aGrt Solutions, Inc.2006—
−2K081141Combocare 2000Xanacare Technologies, LLC2008—
−1K083202Combocare 2000Xanacare Technologies, LLC2008—
0 (this device)K160246SimulCare II (TM)Xanacare Technologies, LLC2016—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
198810
199610
199710
199810
200240
200510
200720
FIG. 1 — Lineage of K160246, 2000–2016Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GZJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GZJ device

  1. #1 K252767 actiTENS miniscore 13.1 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K083202Combocare 2000
Summary page 4
…Product code: ILY & name: Pain Relief ISA Predicate K083202, K081141 devices: Device description: The SimulCare II Multi-function Therapeutic Device is modified from the SimulCare and Combo…
Xanacare Technologies, LLC2008—
*K081141Combocare 2000
Summary page 4
…t code: ILY & name: Pain Relief ISA Predicate K083202, K081141 devices: Device description: The SimulCare II Multi-function Therapeutic Device is modified from the SimulCare and ComboCare 2000…
Xanacare Technologies, LLC2008—

Also cleared against K083202: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 16 years and passes through 5 companies; a new generation was cleared every 1.7 years on median.
  • None of the 18 ancestors has a recall.
  • 1 other device also cites its predicate K083202.

How does its category compare?

All GZJ devices

GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · GZJ

1in 2025

2007: 132008: 112009: 162010: 52011: 52012: 122013: 22014: 42015: 32016: 32017: 32018: 22019: 32020: 42021: 32022: 42023: 12024: 32025: 12026 (partial year): 2
2007high 16 (2009) · low 1 (2023)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GZJ

207in 2024

2007: 223 days median2008: 136 days median2009: 155 days median2010: 232 days median2011: 168 days median2012: 154 days median2014: 344 days median2015: 202 days median2016: 163 days median2017: 113 days median2019: 156 days median2020: 183 days median2021: 231 days median2022: 175 days median2024: 207 days median
2007high 344 (2014) · low 113 (2017)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GZJ

1in 2011

2007: 42008: 12011: 1
2007high 4 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GZJ

13in 2025

2007: 42008: 452009: 172010: 222011: 222012: 202013: 102014: 232015: 182016: 322017: 582018: 212019: 72020: 102021: 52022: 42023: 392024: 122025: 13
2007high 58 (2017) · low 4 (2007)2025

MAUDE reports naming product code GZJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071322344
200811136145
200916155017
20105232022
20115168122
201212154020
20132—010
20144344023
20153202018
20163163032
20173113058
20182—021
2019315607
20204183010
2021323105
2022417504
20231—039
20243207012
20251—013
20262—0—

What is it indicated for?

The SimulCare II™ is intended for the temporary relief of minor muscle and joint pain, promoting the relaxation of

muscle tissue, temporarily increasing local blood circulation, symptomatic relief and management of chronic intractable

pain, and adjunctive relief of post-surgical or post-traumatic pain.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K160246: SimulCare II (TM).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K160246

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026